NEW YORK, April 02, 2018 -- Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the enhancement of its Healthcare Equity Research practice with the promotion of Dr. Jason McCarthy, Ph.D. to Senior Managing Director of Biotechnology.
“Maxim Group continues to build one of the premier proprietary research platforms on Wall Street, with an emphasis on emerging growth and paradigm-shifting businesses. Biotechnology is an important vertical in our healthcare practice and we are proud to have Jason leading this effort,” said Anthony V. Vendetti, Executive Managing Director of Research for Maxim Group. The biotechnology team currently covers over 50 research names and expects to double research coverage over the next year as more resources are added to build out this important vertical.
In his expanded role, Dr. McCarthy will work with Anthony Vendetti in the development and implementation of Maxim Group’s biotechnology research strategy with a key focus on product expansion on the Institutional and Wealth Management platforms. Dr. McCarthy received his doctoral degree in Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.
Michael Rabinowitz, Chairman & CEO of Maxim Group, added “Our commitment to build a first class healthcare practice has never wavered, and Dr. McCarthy’s well-deserved promotion is another significant step in that process. As we continue our firm-wide expansion, we expect to add other high quality professionals to the Maxim Group Research team.”
About Maxim Group LLC
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
For further information please contact:
John J. Garrity
Chief Marketing Officer
212.895.3624
[email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Anta Sports Expands Global Footprint With Strategic Puma Stake
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



